CTOs on the Move


 
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.vyriad.com
  • 2900 37th Street NW Building 110
    Rochester, MN USA 55901
  • Phone: 507.289.0944

Executives

Name Title Contact Details

Funding

Vyriad raised $24.3M on 11/22/2019

Similar Companies

BridgeBio

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Predictive Diagnostics

Predictive Diagnostics is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affymax

Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal

SomaGenics

SomaGenics is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.